English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduOn March 8, the U.S. Food and Drug Administration approved a new indication for the use of semaglutide (brand Wegovy) to “reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or…
Tag: Wegovy
Should heart patients consider taking weight loss medications?
Over the last year, prescriptions for medications that can accelerate weight loss in people with diabetes, or without it, have skyrocketed. But how can these weight loss medications affect the heart? A preventive cardiologist shares how this shifting landscape might affect cardiovascular care and how he advises his patients.
Physician Dispels Myths and Shares Insight Ahead of American Diabetes Month
More than 37 million Americans have been diagnosed with diabetes, with another 8.5 million believed to be living with the condition undiagnosed. In addition, 38 percent of the United States adult population is estimated to have prediabetes, a serious condition…
Researchers at UC Irvine issue a warning that GLP-1RA’s may be dangerous for children
A team of clinicians, exercise scientists, pharmaceutical scholars, ethicists, and behavioral experts at the University of California, Irvine, outlined their concerns that the use of glucagon-like peptide-1 receptor agonists (GLP-1RA’s) to treat childhood obesity and type 2 diabetes may have unintended and adverse consequences for children’s health.
MEDIA ADVISORY: Cedars-Sinai Experts Available to Discuss Safety, Benefits of Using Medications to Lose Weight
The science is unclear on exactly why an increasingly popular new class of federally approved diabetes and obesity medications work, but they do know that they are effective at helping people lose weight.